Q-omics provides the consensus-scored MIR222HG profile across patient tissues and cancer cell-line models. MIR222HG expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MIR222HG is differentially expressed in 16, with the highest sampling consensus in THCA. Additionally, MIR222HG RNA expression shows 16,747 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, THCA, and GBM as cancer lineages where MIR222HG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR222HG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR222HG survival associations across molecular data types. MIR222HG RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR222HG RNA expression–survival associations across cancer types. High MIR222HG expression shows unfavorable associations in KIRC, MESO, COAD and LGG, but favorable associations in SKCM and LAML. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MIR222HG RNA expression.
This table summarizes MIR222HG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR222HG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR222HG shows lower tumor expression in KIRC, BRCA, BLCA and UCEC and higher tumor expression in THCA and COAD. The THCA box plot shows higher MIR222HG RNA expression in tumor versus normal tissue (log2 FC = +2.421, t-test p < 0.001).
This table shows molecular features associated with MIR222HG in patient tissues and cancer cell lines. In patient samples, MIR222HG shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
